XEML
Xtrackers Europe Market Leaders ETF
$25.74
Xtrackers Europe Market Leaders ETF (XEML) Price & Chart
XEML ETF Chart & Stats
$25.74
At close: 4:00 PM EST- Day’s Range
- $25.74 - $25.74
- 52-Week Range
- $23.66 - $27.38
- Previous Close
- $25.84
- Volume
- 12
- Average Volume (3M)
- 52
- AUM
- 5.13M
- NAV
- 25.61
- Expense Ratio
- 0.35%
- Holdings Count
- 39
- Beta
- 0.67
- Inception Date
- Dec 23, 2025
- Last Dividend Ex-Date
- Sep 18, 2026
- Dividend Yield
- (1.90%)
- Shares Outstanding
- 200,001
- Standard Deviation
- N/A
ETF Overview
Xtrackers Europe Market Leaders ETF
The Xtrackers Europe Market Leaders ETF (ticker: XEML) is a compelling investment vehicle designed for those seeking exposure to the upper echelons of the European equity market. As a Size and Style-focused ETF, XEML zeroes in on the Total Market with a particular emphasis on capturing the essence of Europe's most formidable market players. This passively managed fund meticulously tracks an index comprising the top 40 European companies, selected through rigorous fundamental criteria. These companies are then dynamically weighted according to their market capitalization, ensuring that the ETF remains representative of the market's true leaders. By investing in XEML, investors gain access to a broad-based niche that not only highlights market dominance but also offers a diversified perspective on Europe's economic powerhouses. This ETF is an ideal choice for those looking to balance risk with the potential for substantial returns, leveraging the stability and growth potential of Europe's leading corporate entities.
- Asset Class
- Equity
- Region
- Europe
- Issuer
- Xtrackers
- Index Tracked
- STOXX Europe Total Market Leaders Index - USD - Benchmark TR Net
- Ticker Symbol
- XEML
XEML ETF News
AstraZeneca Advances New Ovarian Cancer Combination Study
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s TREVI-OC-02 study is testing torvutatug samrotecan with bevacizumab as first-line maintenance treatment for advanced ovarian, fallopian
5d agoAZN
AstraZeneca Advances China Cancer Trial as Durvalumab Takes Center Stage
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s Phase 3 MATTERHORN-CN study is testing treatment for Chinese patients with operable gastric and gastroesophageal junction
5d agoAZN
XEML ETF FAQ
What was XEML’s price range in the past 12 months?
XEML’s lowest price in the past 12 months was $23.66 and its highest was $27.38.
What is the AUM of XEML?
As of Nov 11, 2026, the AUM of XEML is $5.13M.
Is XEML overvalued?
Based on Wall Street analyst price targets for XEML’s holdings, XEML’s price is currently undervalued.
Does XEML pay dividends?
Yes. XEML pays dividends quarterly. Its most recent dividend was $0.03 per share, and its annual dividend yield is 1.90%. See more information on XEML dividends here.
How many shares outstanding does XEML have?
XEML has 200,001 shares outstanding.
